Sign up for email alert when new content gets added: Sign up
20% of the global population. Patients complain of difficulty in passing stools and defecation. Diagnosis of constipation is based on visual images, specific questionnaires and the knowledge of the patients’ history. Current treatments are based on life style and dietary modification as first strategy, then patients can require the use of products that improves bowel movements using different mechanism of actions. Nowadays, osmotic laxatives represent the first strategy used in the treatment of constipation. Among them, Macrogol 4000 has been largely described to be effective and safe in the treatment of constipation in adults and children. Together with this, bulk-forming laxatives are employed as well. Psyllium fiber belongs to this class of laxatives and among fibers has been shown to be the most effective one. Starting from this evidence, we aimed to verify and confirm the efficacy and safety of two medical devices based on Macrogol 4000 alone (Macrostip®) or in combination with psyllium fiber (Macrostip® Psyllium). In this multicenter, non-comparative and observational study we collected clinical data that support the use of both products for the treatment of constipation in adults. Indeed, data analysis revealed that 15 days treatments are sufficient to improve constipation status in subjects treated with Macrostip® or Macrostip® psyllium. In addition, both treatments resulted to be safe, well tolerated and appreciated by participants supporting the use of these molecules in case of constipation.
